Back to search
FDAFDA · Food and drugs·Recall number D-0488-2017

Levothyroxine Sodium 135 mcg/Liothyronine 15 mcg SR capsules, 90 count bottles, Rx only, Moore's Pharmacy Compounding, Corpus Christi, TX

Published March 1, 2017 · Recall initiated: September 12, 2016

Summary

FDA records drug Class II recall D-0488-2017, published March 1, 2017 and initiated September 12, 2016. Recalling firm: MOORE'S COMPOUNDING PHARMACY; Status: Terminated; Reported quantity: 90 capsules; Lot: 2016-08-22:37@28, exp 2/18/2017. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Superpotent Drug and Subpotent Drug; potency failures obtained

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
MOORE'S COMPOUNDING PHARMACY
Distributor
TX
Lot
2016-08-22:37@28, exp 2/18/2017
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Levothyroxine Sodium 135 mcg/Liothyronine 15 mcg SR capsules, 90 count bottles, Rx only, Moore's Pharmacy Compounding, Corpus Christi, TX recalled?

Yes. FDA published recall D-0488-2017 on March 1, 2017. Reported hazard: Superpotent Drug and Subpotent Drug; potency failures obtained

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit